Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
101.86
-2.11 (-2.03%)
Jul 23, 2026, 10:36 AM EDT - Market open
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, Rhythm Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $139.73. The average 1-year stock price forecast is 37.18% higher than the current stock price, while the lowest is $105 (+3.08%) and the highest is $159 (+56.10%).
Price Target: $139.73 (+37.18%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Reiterates $155 | Buy | Reiterates | $155 | +52.17% | Jul 16, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 15, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $151 | Buy | Maintains | $151 | +48.24% | Jul 8, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $137 → $141 | Buy | Maintains | $137 → $141 | +38.43% | Jul 7, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $130 | Buy | Maintains | $130 | +27.63% | Jun 17, 2026 |
Financial Forecast
Revenue This Year
298.80M
from 189.76M
Increased by 57.47%
Revenue Next Year
539.16M
from 298.80M
Increased by 80.44%
EPS This Year
-3.24
from -3.11
EPS Next Year
-0.73
from -3.24
EPS and Forward PE are based on non-GAAP adjusted numbers.